US appeals court revives Teva lawsuit against Eli Lilly over migraine drug

The U.S. Court of Appeals for the Federal Circuit revived Teva Pharmaceutical's patent lawsuit against Eli Lilly over competing migraine drugs Ajovy and Emgality. The appeals court reversed a Massachusetts judge's 2023 decision invalidating Teva's patents and overturning a $176.5 million jury verdict. Teva sued in 2018 alleging Emgality infringed patents related to antibody treatments. The case returns to Massachusetts federal court. Goodwin Procter represents Teva; Finnegan Henderson represents Lilly.